Home
CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab’s Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab’s Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

Today’s Highlights January 28, 2021

CASI Pharmaceuticals Partner, BioInvent International, Announced Positive Interim Results for NHL
CASI Pharmaceuticals (CASI) partner BioInvent International (This content is for paid subscribers.

Please click here to subscribe or here to log in.
Today’s Highlights
,
January 28, 2021

Other Articles